Colorized scanning electron micrograph of a human cell heavily infected with SARS-CoV-2 virus particles (red). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID
A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, in a subgroup of patients who required high-flow oxygen, investigators found that interferon beta-1a was associated with more adverse events and worse outcomes. These findings were published today (October 18, 2021) in the journal The Lancet Respiratory Medicine.